Equity · Healthcare
LEGN
NASDAQLegend Biotech (LEGN)
This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers.
- Revenue from contracts with customers, year to Dec 2025
- 1.0B USD
- EPS, diluted, year to Dec 2025
- −0.81 USD
- 52-week range
- 16.65 USD – 42 USD
- Avg volume
- 584.2K
as of Aug 3, 2026
Have Legend Biotech (LEGN) insiders bought or sold shares recently?
In the 90 days to 22 Nov 2026, Legend Biotech insiders reported 2 open-market sales and 3 purchases (SEC Form 4).
Form 4, 90 days to 22 Nov 2026, newest reported trade 17 Nov 2026
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 17 Nov 2026 | Zhang IngridChief Executive Officer | Buy | 20,000 | 163K USD |
| 13 Nov 2026 | Salovey PeterDirector | Buy | 10,000 | 90K USD |
| 12 Nov 2026 | Salovey PeterDirector | Buy | 10,000 | 94K USD |
| 29 Sep 2026 | Sanders Corazon (Corsee) D.Director | Sell | 27,370 | 259K USD |
| 21 Sep 2026 | Santos Carlos EChief Financial Officer | Sell | 5,430 | 50K USD |
| Bought | 3 open-market purchases | 40,000 | $346K | |
| Sold | 2 open-market sales | 32,800 | $309K |
8 other filings in the window: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 24 Sep 2026 | Casey Patrick JohnDirector | Award | 20,986 | |
| 24 Sep 2026 | Heyman Tomas J.Director | Award | 20,986 | |
| 24 Sep 2026 | Ji Darren XiaohuiDirector | Award | 28,330 | |
| 24 Sep 2026 | Sanders Corazon (Corsee) D.Director | Award | 20,986 | |
| 24 Sep 2026 | Salovey PeterDirector | Award | 28,330 | |
| 24 Sep 2026 | Mao LiDirector | Award | 20,986 | |
| 21 Sep 2026 | Santos Carlos EChief Financial Officer | Award | 19,676 | |
| 15 Sep 2026 | Zhang IngridChief Executive Officer | Award | 1,131,860 |
Which funds hold Legend Biotech (LEGN)?
7 of the 45 institutional funds we track reported a Legend Biotech position for the quarter ended 30 Sep 2026 — a combined 121.4M USD; the latest of those filings landed 16 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Point72 Asset Management | Trimmed | 1,604,466 | 31.9M USD | −47.8% |
| Two Sigma Investments | Added | 1,522,163 | 30.3M USD | +828.7% |
| Renaissance Technologies | Held (±25%) | 1,227,300 | 24.4M USD | +22.7% |
| Balyasny Asset Management | Added | 1,178,042 | 23.4M USD | +458.3% |
| Citadel Advisors | Added | 493,310 | 9.8M USD | +1,344.9% |
| Tudor Investment Corp | Added | 69,942 | 1.4M USD | +140.6% |
| Marshall Wace | Trimmed | 10,434 | 208K USD | −94.8% |
What has been filed or recorded for Legend Biotech (LEGN)?
The filings we hold for Legend Biotech, newest first: 6 fails-to-deliver days and 5 reported financial figures, the latest dated 30 Oct 2026.
| And | ||||
|---|---|---|---|---|
| 30 Oct 2026 | Fails to deliver | Shares failed to deliver | 340 shares | 8K USD notional · <0.001% of shares out |
| 29 Oct 2026 | Fails to deliver | Shares failed to deliver | 47,408 shares | 1.1M USD notional · 0.013% of shares out |
| 22 Oct 2026 | Fails to deliver | Shares failed to deliver | 44,445 shares | 828K USD notional · 0.012% of shares out |
| 16 Oct 2026 | Fails to deliver | Shares failed to deliver | 33 shares | 653 USD notional · <0.001% of shares out |
| 15 Oct 2026 | Fails to deliver | Shares failed to deliver | 66,772 shares | 1.3M USD notional · 0.018% of shares out |
| 14 Oct 2026 | Fails to deliver | Shares failed to deliver | 15,625 shares | 279K USD notional · 0.004% of shares out |
| 31 Dec 2025 | Financials | Revenue from contracts with customers | 1.0B USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | −296.8M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted earnings loss per share | −0.81 USD | fiscal year |
| 31 Dec 2025 | Financials | Total assets | 1.7B USD | at period end |
| 31 Dec 2025 | Financials | Equity | 1.0B USD | at period end |
What do people ask about Legend Biotech (LEGN)?
What is Legend Biotech’s revenue?1.0B
Legend Biotech reported revenue from contracts with customers of 1.0B USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Legend Biotech insiders bought or sold shares recently?2 sales
In the 90 days to 22 Nov 2026, Legend Biotech insiders reported 2 open-market sales and 3 purchases (SEC Form 4). A further 8 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders
Which funds own Legend Biotech?7 of 45
7 of the 45 funds we track reported a Legend Biotech position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were Point72 Asset Management, Two Sigma Investments and Renaissance Technologies. See Funds

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close)
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 31 Dec 2025